CADL — Candel Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$12.78
-$0.07 (-0.58%)
Candel Therapeutics Inc (CADL) is a biotechnology company listed on NASDAQ. It is led by Paul-Peter Tak FOCIS, M.D., Ph.D., based in 117 Kendrick Street, Needham, MA, United States, 02494, with about 55 employees. Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Net income was -$8.7M. CADL currently screens at market cap $592.0M.
Use this CADL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CADL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CADL SEC filings page. Lician reads the product cache first so this HTML stays unique to Candel Therapeutics Inc even when a live quote feed is slow.
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
CADL Key Statistics
Market Cap
$592.02M
Volume
431,027
Previous Close
$12.86
Day Range
$12.97 – $13.70
P/B Ratio
4.24
EPS
-$1.74
Revenue
$0.00
Net Income
-$55.18M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
55
CADL Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $125.00K | $125.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$55.18M | -$37.94M | -$18.79M | -$36.12M |
| EPS (Diluted) | -$1.74 | -$1.31 | -$0.65 | -$1.91 |
Total Assets
$106.87M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$102.65M
Operating Cash Flow
-$27.02M
Free Cash Flow
$0.00
Candel Therapeutics Inc Company Information
- President, CEO & Director
- Paul-Peter Tak FOCIS, M.D., Ph.D.
- Headquarters
- 117 Kendrick Street, Needham, MA, United States, 02494
- Website
- www.candeltx.com
- Phone
- 617 916 5445
- IPO / Founded
- 2021-07-27
- Sector
- Healthcare
- Industry
- Biotechnology